Despite increased spending, the breast cancer detection rate and stage did not change, according to a new JNCI study.
Medicare's mammography costs increased by almost 50% over a 7-year period while the breast cancer detection rate and stage at diagnosis did not change, a 270,000-patient study showed.
Annual Medicare spending rose from $666 million during 2001 to 2002, to $962 million in 2008 to 2009, according to Cary P. Gross, MD, of Yale University, and colleagues. The number of women screened and detection rates for early-stage disease were similar during the two time periods.
The rise in cost coincided with widespread transition from plain-film to more expensive digital mammography, they reported online in the Journal of the National Cancer Institute.
"I view this as important preliminary data suggesting there has been no improvement whatsoever [in detection rates]," Gross told MedPage Today. "As far as why there was no improvement, it's either because the new technology was not more effective or maybe we just need longer follow-up time, and only time will tell."
Read the original report here: http://bit.ly/1qQh4p4
Source: medpageToday
Trump Administration’s Message to Supreme Court Puts New Wrinkle in Braidwood Case
February 21st 2025The Trump administration argues that HHS Secretary Robert F. Kennedy Jr can overrule the US Preventive Services Task Force to determine the preventive services covered under the Affordable Care Act.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
5 Key Health Care Moments During President Trump's First Month Back in Office
February 21st 2025President Donald J. Trump pushed for significant health care changes during his first month back in office, through executive orders affecting managed care, drug pricing, and clinical trial diversity guidance.
Read More